The Wall Street Journal (online registration required): A Food and Drug Administration rebuke of televised comments made by Aegerion Pharmaceuticals Inc. ’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.
The emails shed light on the regulator’s oversight of marketing in the Internet age, where comments that might have aired once and been forgotten in the past can now easily be retrieved through a Google search.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now